The Economist asks
Before 1 October 2017, will the FDA approve the sale of a gene-therapy treatment for inherited diseases?
Started
Jan 24, 2017 06:00PM UTC
Closed Oct 01, 2017 05:00PM UTC
Closed Oct 01, 2017 05:00PM UTC
Challenges
Tags
Congress passed the 21st Century Cures Act in December 2016, meant to accelerate the discovery, development, and delivery of new cures (US Congress). Spark Therapeutics could become the first company to receive FDA approval to sell a gene-therapy treatment in the U.S. (The Economist, Technology Review, FDA Cellular Gene Therapy Products, Nature Journal, FDA Development Approval Process).
Confused? Check our FAQ or ask us for help.
If you liked this question, you might also enjoy forecasting on whether the US will enact a soda tax in 2017 or on whether the FAA will grant Amazon a waiver to begin testing UAV delivery systems.
Although the FDA approved the sale of a new gene therapy for acute lymphoblastic leukemia, they did not approve the sale of any gene therapy for inherited diseases. This question closed "b) No," with and end date of 1 October 2017. See our FAQ to learn about how we resolve questions and how scores are calculated.
If you liked this question, you might also enjoy forecasting on whether the US will enact a soda tax in 2017 or on whether the FAA will grant Amazon a waiver to begin testing UAV delivery systems.
Although the FDA approved the sale of a new gene therapy for acute lymphoblastic leukemia, they did not approve the sale of any gene therapy for inherited diseases. This question closed "b) No," with and end date of 1 October 2017. See our FAQ to learn about how we resolve questions and how scores are calculated.
Possible Answer | Correct? | Final Crowd Forecast |
---|---|---|
Yes | 1.00% | |
No | 99.00% |
Crowd Forecast Profile
Participation Level | |
---|---|
Number of Forecasters | 495 |
Average for questions older than 6 months: 187 | |
Number of Forecasts | 1052 |
Average for questions older than 6 months: 542 |
Accuracy | |
---|---|
Participants in this question vs. all forecasters | average |